Horgan Denis, Hofman Paul, Buttner Reinhard, Rieß Olaf, Lugowska Iwona, Dube France, Singh Jaya, Nadal Ernest, Stokłosa Tomasz, Sīviņa Elīna, Van der Buckle Marc, Mosoiu Silvia, Bertolaccini Luca, Girard Nicolas, Meerbeeck Jan Van, Omar Imran, Capoluongo Ettore D, Bielack Stefan, Hills Tanya, Baldwin David, Subbiah Vivek
European Alliance for Personalised Medicine, Brussels, Belgium.
Department of Molecular and Cellular Engineering, Faculty of Engineering and Technology, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, India.
Diagnosis (Berl). 2024 Aug 1;12(1):94-107. doi: 10.1515/dx-2024-0092. eCollection 2025 Feb 1.
This paper aims to identify and address gaps in cancer treatment and diagnosis within European health services, focusing specifically on discrepancies between clinical guidelines and policy guidelines. It seeks to highlight how the underutilization of advanced diagnostic techniques recommended by medical societies contributes to missed opportunities for improving patient outcomes.
A comprehensive analysis was conducted across multiple European countries to assess the compliance and integration of clinical guidelines with the availability of advanced diagnostic technologies. Secondary data related to clinical and policy guidelines in cancer care were collected and analyzed. Key indicators of adoption and utilization of next-generation sequencing and liquid biopsy were examined to evaluate their impact on health service efficiency and patient care.
The analysis revealed significant discrepancies between the recommendations of medical societies regarding advanced diagnostic techniques and their adoption in health policy decisions across Europe. Country-specific assessments indicated varying levels of alignment between clinical guidelines and the availability of advanced diagnostics. These findings underscored missed opportunities for optimizing patient care and health service efficiency through better alignment and integration of clinical guidelines with policy decisions.
This study concludes that there is a critical need for health policy decision-makers to prioritize the adoption of clinical guidelines in resource allocation and health service organization. Greater attention to the recommendations of medical societies regarding advanced diagnostic techniques could significantly enhance diagnostic accuracy, treatment efficacy, and overall patient outcomes in cancer care. The paper advocates for policy reforms that acknowledge and leverage the potential benefits of advanced diagnostics in improving health service performance and patient-centered care across Europe.
本文旨在识别并解决欧洲医疗卫生服务中癌症治疗和诊断方面的差距,特别关注临床指南与政策指南之间的差异。它试图强调医学协会推荐的先进诊断技术未得到充分利用如何导致改善患者治疗结果的机会错失。
对多个欧洲国家进行了全面分析,以评估临床指南与先进诊断技术可用性的合规性和整合情况。收集并分析了与癌症护理临床和政策指南相关的二手数据。研究了下一代测序和液体活检的采用和利用关键指标,以评估它们对卫生服务效率和患者护理的影响。
分析揭示了医学协会关于先进诊断技术的建议与其在欧洲各地卫生政策决策中的采用之间存在重大差异。各国具体评估表明临床指南与先进诊断技术可用性之间的一致性程度各不相同。这些发现强调了通过更好地使临床指南与政策决策保持一致和整合来优化患者护理和卫生服务效率的机会错失。
本研究得出结论,卫生政策决策者迫切需要在资源分配和卫生服务组织中优先采用临床指南。更多关注医学协会关于先进诊断技术的建议可显著提高癌症护理中的诊断准确性、治疗效果和患者总体治疗结果。本文倡导进行政策改革,承认并利用先进诊断技术在改善欧洲卫生服务绩效和以患者为中心的护理方面的潜在益处。